Pritumumab

Pritumumab is a human monoclonal antibody against vimentin[1] developed by Nascent Biotech. It is in clinical trials for the treatment of glioma.[2] The FDA granted orphan drug designation in 2015.

Pritumumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
Targetvimentin
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6440H9968N1708O2016S42
Molar mass150 kg/mol g·mol−1
 NY (what is this?)  (verify)

References
  1. WHO Drug Information
  2. Nascent Biologics Proven Cancer Cure Back in the Hands Of U.S. Inventor After 27 Years In Japan


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.